CD274 and esophageal squamous cell carcinoma: Pembrolizumab–chemotherapy also continued to demonstrate a higher ORR compared with placebo–chemotherapy in all randomly assigned patients (56.8% vs 38.8%) and in patients with ESCC (56.7% vs 40.7%), PD-L1 CPS ≥ 10 (60.4% vs 30.6%), and ESCC PD-L1 CPS ≥ 10 (59.1% vs 31.3%).